Constipation is a gastrointestinal condition characterized by infrequent bowel movements, hard stools, or difficulty passing stools, often associated with dietary, behavioral, or medical factors.
A botanical moisturizer with oat and aloe outperformed metronidazole for rosacea erythema and lesions over 12 weeks. A separate study found nine risk factors for rosacea severity, including female sex, family history, and skin care habits.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07765004 |
Probiotics Improve Constipation |
RECRUITING | NA |
| NCT07757061 |
YQD Combined With Plant Lactobacillus for Slow Transit Constipation |
COMPLETED | NA |
| NCT07751224 |
Auricular Acupuncture for Post-Stroke Constipation |
COMPLETED | NA |
| NCT07723729 |
Butyrate Yogurt for Cancer Constipation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07716553 |
Study of Transanal Irrigation vs Standard Care for Constipation, Gut Microbiota, and Motor Disorders in Parkinson's Disease |
NOT_YET_RECRUITING | NA |
| NCT07713810 |
Radicle GI HealthTM VNB: A Study Assessing the Impact of Health and Wellness Products on Constipation and Related Health Outcomes |
RECRUITING | NA |
| NCT07705542 |
Balloon Inflation in Biofeedback |
RECRUITING | NA |
| NCT07668765 |
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity |
NOT_YET_RECRUITING | |
| NCT07656896 |
Measurement of Ultrasonographic Rectal Diameter in Children With Constipation |
ACTIVE_NOT_RECRUITING | |
| NCT07654959 |
Test Anxiety on Bowel Health and Constipation in Students |
RECRUITING |
